{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:19:15Z","timestamp":1775726355178,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,18]]},"DOI":"10.7759\/cureus.60567","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T01:36:57Z","timestamp":1716082617000},"source":"Crossref","is-referenced-by-count":1,"title":["Macrophage Activation Syndrome Presents as Initial Manifestation of Lupus in an Adult Female"],"prefix":"10.7759","author":[{"given":"Ahmed H","family":"Abdelfattah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Macpherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121233","article-title":"Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome","volume":"40","author":"Strippoli R","year":"2013","unstructured":"Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. 2013, 40:761-7. 10.3899\/jrheum.121233","journal-title":"J Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory B","year":"2023","unstructured":"Shakoory B, Geerlinks A, Wilejto M, et al.. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann Rheum Dis. 2023, 82:1271-85. 10.1136\/ard-2023-224123","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2227-1","article-title":"Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review","volume":"32","author":"Vilaiyuk S","year":"2013","unstructured":"Vilaiyuk S, Sirachainan N, Wanitkun S, Pirojsakul K, Vaewpanich J. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol. 2013, 32:899-904. 10.1007\/s10067-013-2227-1","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309354906","article-title":"Hemophagocytic syndrome as one of the main primary manifestations in acute systemic lupus erythematosus--case report and literature review","volume":"19","author":"Carvalheiras G","year":"2010","unstructured":"Carvalheiras G, Anjo D, Mendon\u00e7a T, Vasconcelos C, Farinha F. Hemophagocytic syndrome as one of the main primary manifestations in acute systemic lupus erythematosus--case report and literature review. Lupus. 2010, 19:756-61. 10.1177\/0961203309354906","journal-title":"Lupus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2013.09.004","article-title":"[Hemophagocytic syndrome as the initial manifestation of systemic lupus erythematosus]","volume":"10","author":"Eg\u00fces Dubuc CA","year":"2014","unstructured":"Eg\u00fces Dubuc CA, Uriarte Ecenarro M, Meneses Villalba C, Aldasoro C\u00e1ceres V, Hernando Rubio I, Belzunegui Otano J. [Hemophagocytic syndrome as the initial manifestation of systemic lupus erythematosus]. Reumatol Clin. 2014, 10:321-4. 10.1016\/j.reuma.2013.09.004","journal-title":"Reumatol Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24883","article-title":"Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients","volume":"60","author":"Parodi A","year":"2009","unstructured":"Parodi A, Dav\u00ec S, Pringe AB, et al.. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009, 60:3388-99. 10.1002\/art.24883","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.932042","article-title":"Erythematosus plaques with macrophage infiltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus","volume":"26","author":"Tochihara M","year":"2016","unstructured":"Tochihara M, Kasai M, Katsumata Y, et al.. Erythematosus plaques with macrophage infiltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol. 2016, 26:956-7. 10.3109\/14397595.2014.932042","journal-title":"Mod Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2013.12.009","article-title":"Macrophage activation syndrome as the initial manifestation of severe juvenile onset systemic lupus erythematosus. Favorable response to cyclophosphamide","volume":"10","author":"Jim\u00e9nez AT","year":"2014","unstructured":"Jim\u00e9nez AT, Vallejo ES, Cruz MZ, Cruz AC, Jara BS. Macrophage activation syndrome as the initial manifestation of severe juvenile onset systemic lupus erythematosus. Favorable response to cyclophosphamide. Reumatol Clin. 2014, 10:331-5. 10.1016\/j.reumae.2013.12.009","journal-title":"Reumatol Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314529467","article-title":"Clinical features of macrophage activation syndrome in the adult northern Chinese population","volume":"23","author":"Li X","year":"2014","unstructured":"Li X, Qu B, Nie Y, Zhu G, Li W, Mu F. Clinical features of macrophage activation syndrome in the adult northern Chinese population. Lupus. 2014, 23:785-92. 10.1177\/0961203314529467","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert GS","year":"2014","unstructured":"Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014, 28:277-92. 10.1016\/j.berh.2014.03.002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu B","year":"2020","unstructured":"Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. J Autoimmun. 2020, 111:102452. 10.1016\/j.jaut.2020.102452","journal-title":"J Autoimmun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318205092d","article-title":"Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids","volume":"17","author":"Bruck N","year":"2011","unstructured":"Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011, 17:23-7. 10.1097\/RHU.0b013e318205092d","journal-title":"J Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313504634","article-title":"Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus","volume":"22","author":"Bakshi J","year":"2013","unstructured":"Bakshi J, Hassan S, D'Cruz D, Chan A. Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus. Lupus. 2013, 22:1544-6. 10.1177\/0961203313504634","journal-title":"Lupus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253847-macrophage-activation-syndrome-presents-as-initial-manifestation-of-lupus-in-an-adult-female","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T01:37:02Z","timestamp":1716082622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253847-macrophage-activation-syndrome-presents-as-initial-manifestation-of-lupus-in-an-adult-female"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.60567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,18]]}}}